Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
Medtronic‘s today released data from a retrospective analysis of patients with its Reactive ATP therapy, touting slowed atrial fibrillation progression for individuals with implanted cardiac devices.
Data came from a retrospective analysis of approximately 8,800 patients and was presented at the EHRA Europace-Cardiostim 2017 meeting, Fridley, Minn.-based Medtronic said. Read more
The FDA today released information on a select voluntary recall from Getinge‘s Datascope and Maquet of its System CS100, CS100i and CS300 intra-aortic balloon pumps over issues with potential electrical test failures.
Datascope said they received a complaint in which the device failed to initiate therapy, resulting in a patient death. The complaint involved a CS300 IABP device which failed to pump due to electrical test failure code #58, a maintenance code and an autofill failure, according to the FDA notice. Read more
BTG touted data last week showing that patients with chronic deep vein thrombosis and post-thrombotic syndrome can be safely and effectively treated with the Ekos device and anti-coagulation drugs.
The study’s protocol is the 1st treatment regimen proven to reduce the symptoms of PTS and demonstrate an improvement in quality of life for patients with DVT. Read more
An activist fund run by Daniel Loeb is said to be amassing a stake in Dutch healthcare giant Philips ahead of a possible proxy war next year.
Third Point, named for a wave break popular with surfers off of Malibu, could be looking to acquire a “multi-billion-euro position” in Philips, anonymous sources told the Times of London. The exact size of the stake is unclear, the newspaper reported. Read more
Novadaq Technologies said today that it agreed to a $700 million offer from Stryker for its line of fluorescence imaging technology.
Mississauga, Ontario-based Novadaq said the $11.75-per-share offer is a 95.8% premium on its $6 closing price June 16, for a valuation of roughly $701 million; Stryker said that includes some $47 million in net cash. The deal, expected to close during the 3rd quarter, includes a $21 million breakup fee provision, Novadaq said. Read more